Arkolith/Insider Trading/APRE/Form 4

Hamill John P.

SrVP/CFO/Prin Fin & Acct OfcrAprea Therapeutics, Inc. (APRE) · full profile →Form 4 · filed Apr 1, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 31, 2026Buy(P)31K$0.81$25K31K
Mar 31, 2026Buy(P)31K——31K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-038522) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML